The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
TCT 2021 | Infusion of CD30 CAR T-cells following AuHCT in patients with lymphoma
Marcie Riches, MD, MS, The University of North Carolina at Chapel Hill, Chapel Hill, NC, discusses the results of a Phase I multicenter study evaluating the use of CD30 CAR T-cell infusion following autologous transplant (AuHCT) in patients with relapsed/refractory lymphoma. The results of this study demonstrate CD30 CAR-T infusion is safe and well-tolerated, with a 1-year progression-free survival of 79% in patients with Hodgkin lymphoma. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.
